switch to tirzepatide from semaglutide Switching Officially made the switch from

, Theodorakis, M

Why it matters: Testing both IGF-1 and IGFBP-3 together provides a more complete picture of growth hormone activity

The first-month results on semaglutide typically show 3-5 pounds of loss, with the pace accelerating as doses increase

These side effects typically resolve on their own without treatment

Clinically, semaglutide is prescribed for several conditions: Type 2 diabetes Obesity and chronic weight management Metabolic disorders involving insulin resistance The drug itself is identical across different brand names, but approved for different purposes

La enfermedad cardiovascular es la primera causa de mortalidad en el mundo, explicando alrededor del 30% de todas las muertes